Obermatt
See Similar Stocks →

Kyongbo Pharmaceutical

KSC:214390 · KR7214390007
PharmaceuticalsSmall

360

11
Medium confidence — indicative
Profit price61
Owner Earnings Yield1
Dividend Yield1
Price/Sales56
EV / Gross Profit51
Price/Book51
Return on Capital61
Cash Return on Capital28
Return on Equity58
EBIT Margin50
Gross Profitability68
Cash Conversion100
Accruals8
Owner Earnings Margin17
Sales growth58
Profit Growth94
Long-Term EPS Growth17
Reinvestment92
Price momentum64
Debt load20
Refinancing88
Debt Payback1
Liquidity31
Analyst ratings—
Expectations trend—
Market mood5
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Kyongbo Pharmaceutical doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Employees8
Websitekbpharma.co.kr
ISINKR7214390007
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
Health DiagnosticsInfectious DiseasesCardiovascularOncology

Description

Analysis

Middle-of-the-road

Kyongbo Pharmaceutical Co., Ltd sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is fragile. The company scores 6/20 on our value-creation score: not creating value.

Flags to be aware of: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
33
2026

All-time high

33

Jun 2026

All-time low

31

Mar 2026

Average rank

32

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
56
—
—
—
Price/Earnings
7
—
—
—
Price/Book
51
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
42
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Kyongbo Pharmaceutical with its peers
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Samil Pharmaceutical
KSC:000520
28
CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Samsung Pharm
KSC:001360
—
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hana Pharm
KSC:293480
88
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Pyridam Farma
JKT:PYFA
3
CountrySingapore
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Korea United Pharm
KSC:033270
90
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →